

**Everolimus improves the efficacy of dasatinib in the treatment of  
PDGFRA-driven glioma**

Zachary Miklja<sup>1^</sup>, Viveka Nand Yadav<sup>1^</sup>, Rodrigo Cartaxo<sup>1</sup>, Ruby Siada<sup>1</sup>, Brendan Mullan<sup>1</sup>, Stefanie Stallard<sup>1</sup>, Alyssa Paul<sup>1</sup>, Amy K. Bruzek<sup>2</sup>, Kyle Wierzbicki<sup>1</sup>, Tao Yang<sup>4</sup>, Taylor Garcia<sup>1</sup>, Ian Wolfe<sup>1</sup>, Hemant Parmar<sup>6</sup>, Marcia Leonard<sup>1</sup>, Patricia L. Robertson<sup>1</sup>, Hugh Garton<sup>2</sup>, Sriram Veneti<sup>3</sup>, Chandan Kumar-Sinha<sup>3,5</sup>, Arul Chinnaiyan<sup>3,5,8,9</sup>, Rajen Mody<sup>1</sup>, Manjunath P. Pai<sup>11</sup>, Timothy N. Phoenix<sup>12</sup>, Bernard L. Marini<sup>11</sup>, Carl Koschmann<sup>1\*</sup>

\*Correspondence to: [ckoschma@med.umich.edu](mailto:ckoschma@med.umich.edu)

**This PDF file includes:**

Supplementary methods  
Supplementary figure legends

“\*corresponding author”

“^denotes equal contribution”

## **Supplemental materials**

### **Supplementary methods**

#### **P-gp assay**

*In vitro* P-gp inhibitor assay was performed with the Pgp-Glo™ Assay System (Promega). Assay methods were executed as described in the supplied protocol. Briefly, the assay detected the effects of compounds on recombinant human P-gp in a cell membrane fraction. The assay utilized the ATP dependence of the light-generating reaction (firefly luciferase) of ATPase inhibition. Verapamil is a P-gp substrate that stimulates P-gp ATPase activity and, within the assay, functions as a P-gp stimulator (negative control). Sodium orthovanadate ( $\text{Na}_3\text{VO}_4$ ) provides a measure of P-gp independent ATPase activity and was used as a P-gp inhibitor (positive control) within this assay. All experimental conditions were briefly rocked on a plate shaker and then put in an incubator at 37°C and 5%  $\text{CO}_2$  for 3.5 hours. After this incubation period, all conditions were again briefly rocked on a plate shaker and incubated at room temperature for 20 minutes to allow luminescent signal to develop. Luminescent signal (ATM inhibition) was read on a Synergy HTX Multi-Mode microplate reader (BioTek).

#### **Human cerebrospinal fluid tumor DNA (CSF-tDNA) analysis**

Tumor DNA analysis was performed by droplet digital PCR (ddPCR), a highly sensitive PCR method that can detect low copy numbers of DNA, including ctDNA, in CSF. PCR primers and fluorescent probes were designed for the wild-type PDGFRA and mutant D842V sequences, as well as the target amplification region. An additional assay was designed for the housekeeping gene AP3B1 to be used as a reference (Bio-Rad). Patient sample CSF underwent ddPCR to document baseline CSF tDNA in UMPED52 and baseline CSF tDNA PDGFRA copy number in UMPED44. The Bio-Rad QX200 AutoDG system was used for all ddPCR work, and Bio-Rad QuantaSoft Analysis Pro was used for analysis of results.


### **Western blot and immunohistochemistry**

PDGFRA pathway expression was assessed in primary HGG cell cultures and mouse brain/ tumor tissue via immunocytochemistry (1:500) and western blotting (1:1000) with PDGF Receptor  $\alpha$  antibody (Cell Signaling, sc-3174S) and Phospho-PDGF Receptor  $\alpha$  antibody (Cell Signaling sc-3170S). Phospho-AKT expression in PDGFRA-driven HGG mouse brain and tumor tissue was assessed by immunohistochemistry with Phospho-AKT antibody (Cell Signaling, #9271S). P-glycoprotein (P-gp) expression in PDGFRA-driven HGG mouse brain and tumor tissue was assessed by immunohistochemistry (1:50) with P-gp antibody (Santa Cruz Biotechnology, sc-390883).

## **Supplementary Figures**


A

Mouse IUE PDGFRA D842V, Tp53, H3K27M (PPK)




B

PDGFRA western quantification




**Figure S1:** Characterization of IUE PPK generated tumors and primary cell culture **A)** IHC for *IUE* PPK generated tumors depicting high-grade features including necrosis and vascular proliferation (top right box). Tumors demonstrated staining for H3K27M, negative staining for H3K27me3, and increased total PDGFRA. **B)** PDGFRA western quantification for total PDGFRA and p-PDGFR normalized to vinculin signal for PPK cells treated with various dasatinib doses *in vitro*. Scale bars: A(top): left 200  $\mu$ m, right 100  $\mu$ m; (bottom) up 200  $\mu$ m, down 50  $\mu$ m


**A** Sanger Institute – Genomics Of Drug Sensitivity (GDSC)




**B** UMPED58 Dasatinib Monotherapy




**C** UMPED58 (*PDGFRA* amplified) proliferation



**Figure S2:** Sensitivity of human primary cell cultures to treatment with dasatinib **A)** Dasatinib dose-response curve for various cancer types (data from the Sanger Institute – Genomics of Drug Sensitivity). Most low grade glioma and glioblastoma mutiforme cell cultures were sensitive to dasatinib within 0.01 to 1  $\mu\text{M}$  ranges (red region). **B)** UMPED58 (*PDGFRA*-amplified DIPG cell culture) dose response curve with dasatinib monotherapy. **C)** UMPED58 growth response after addition of PDGF ligand  $\alpha$  and  $\beta$  (\*\*\*\*  $P \leq 0.00005$  by Welch's t-test).




**Figure S3:** Dasatinib and everolimus efficacy in PPK neurospheres and P-gp inhibition over time. **A)** Pixel area of the largest PPK neurosphere by fluorescent microscopy for different treatment conditions (\*\* $P \leq 0.0005$ , \*\*\*\*  $P \leq 0.00005$  by Welch's t-test). **B)** P-gp inhibition over time using *in vitro* assay.




**Figure S4:** Pharmacokinetic (PK) analysis of dasatinib concentrations in non-tumor mouse model **A)** Schematic of PK mouse studies (tail vein injection (TVI) and oral gavage (OG)). **B)** Dasatinib plasma concentration (ng/mL) over time for treatment with dasatinib alone and dasatinib with everolimus. **C)** Dasatinib cortex concentration (ng/mL) over time for treatment with dasatinib alone and dasatinib with everolimus. **D)** Dasatinib brainstem concentration (ng/mL) over time for treatment with dasatinib alone and dasatinib with everolimus. **E)** Dasatinib concentration (ng/mL) for plasma, cortex, and brainstem over time when treated with dasatinib alone. **F)** Dasatinib concentration (ng/mL) for plasma, cortex, and brainstem over time when treated with dasatinib and everolimus.






**Figure S5:** PK analysis of everolimus blood and brain concentration in non-tumor mouse model **A)** Everolimus plasma concentrations of (ng/mL) over time after treatment with everolimus. **B)** Everolimus brain concentrations (ng/g) over time after treatment with everolimus.




**Figure S6:** Immunohistochemistry of mouse tumors treated immediately prior to processing. **A)** P-gp expression in the treated condition was shown to be reduced when compared to the untreated condition ( $*** P \leq 0.0005$  by Welch's t-test). Red arrows represent positive staining cells. **B)** pAKT expression in the treated condition was shown to be reduced when compared to the untreated condition ( $* P \leq 0.05$  by Welch's t-test). **C)** PDGFR expression in the treated condition was shown to be reduced when compared to the untreated condition ( $** P \leq 0.005$  by Welch's t-test). Scale bars (from left to right): 200  $\mu$ m; 200  $\mu$ m; 50  $\mu$ m.


### A Plasma



### B CSF




**Figure S7:** Pharmacokinetic analysis of dasatinib concentrations in plasma and CSF in patients **A)** Comparison of plasma dasatinib concentrations for dasatinib alone and dasatinib and everolimus co-treatment for UMPED44 and UMPED52. **B)** Comparison of CSF dasatinib concentrations for dasatinib alone and dasatinib and everolimus co-treatment conditions for UMPED44.




**Figure S8:** Molecular attributes and tumor imaging of *PDGFRA*-mutated tail patient (UMPED52) **A)** UMPED52 copy number profile with estimated tumor content. **B)** UMPED52 somatic variants with a *PDGFRA* variant allele fraction of 34%. **C)** UMPED52 baseline CSF tDNA documenting *PDGFRA* D824V allele fraction. **D)** Serial UMPED52 MRI (axial FLAIR T2) during therapy.


P-gp expression by PDGFRA status



P-gp expression by age at diagnosis



P-gp expression by MGMT status



**Figure S9:** PedcBioPortal (adult HGG) P-gp RNA-seq data **A)** No statistical significance was found between P-gp expression and *PDGFRA* status, age at diagnosis, or *MGMT* status within these adult data sets.